We expect the leading medical devices provider AngioDynamics Inc. (ANGO - Free Report) to beat expectations when it reports fiscal 2014 first quarter results after the closing bell on Oct 10.
Why a Likely Positive Surprise?
Our proven model shows that AngioDynamics is likely to beat earnings estimates because it has the right combination of two key ingredients.
Positive Zacks ESP: Earnings ESP, the difference between the Most Accurate estimate of 4 cents and the Zacks Consensus Estimate of 3 cents, stands at +33.33%.
Zacks Rank #3 (Hold): ANGO currently retains a Zacks Rank #3 (Hold).
The combination of the stock’s Zacks Rank #3 (Hold) and +33.33% ESP makes us confident of a positive earnings beat on Oct 10.
What is Driving the Better than Expected Earnings?
AngioDynamics enjoys leading market share in several of its operating segments including angiographic products and thrombolytic catheters and products. The market served by ANGO is in excess of $1 billion, and continues to grow.
AngioDynamics has delivered solid earnings results in the fourth quarter of fiscal 2013. It has reported more than twofold year-over-year increase in adjusted earnings to 7 cents per share for the quarter, surpassing the Zacks Consensus Estimate by 2 cents. For fiscal 2013, adjusted earnings surged 66.7% to 35 cents per share and beat the Zacks Consensus Estimate by a penny
AngioDynamics expects fiscal 2014 revenues in the range of $346 million–$352 million, up 3% at the top range of the previous guidance. Adjusted earnings per share are expected in the range of 31 cents to 35 cents for the fiscal year, taking into account the impact from the medical device tax.
Other Stocks to Consider
AngioDynamics is not the only bullish company this earnings season. We also see likely earnings beats coming from the following industry peers:
DexCom Inc. (DXCM - Free Report) : Earnings ESP of +15.39% and Zacks Rank #2 (Buy).
Sunshine Heart Inc. : Earnings ESP of +32.50% and Zacks Rank #3 (Hold).
Techne Corp. (TECH - Free Report) : Earnings ESP of +1.25% and Zacks Rank #3 (Hold).